Ocugen, Inc. (OCGN)

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine for COVID-19. Founded in 2013, Ocugen is headquartered in Malvern, Pennsylvania. As of the latest available data, Shankar Musunuri serves as the Chairman and CEO, having co-founded the company with a deep passion for tackling unmet medical needs. While specific financial details like revenue can vary year by year, Ocugen gained significant attention for its partnership with Bharat Biotech to co-develop Covaxin, a COVID-19 vaccine, for the U.S. market. The company's lead gene therapy candidate, OCU400, aims to treat inherited retinal diseases. Ocugen's work is characterized by its commitment to innovation in gene therapy and its aspiration to address significant global health challenges.